In a setback for the Japanese bioventure, AnGes, Inc. has discontinued a government-supported R&D project for an injected DNA plasmid vaccine for the original Wuhan strain of COVID-19.
While the Osaka-based firm said it was currently difficult to predict the business impact of the cancellation for accounting reasons, the move presents another challenge given its only commercialized product, the gene therapy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?